Glaxo Group Limited

Glaxosmithkline Intellectual Property Development Limited

Glaxo Wellcome Inc.

Biota Scientific Management Pty Ltd

Graham George Adam Inglis

Simon John Fawcett MacDonald

Julie Nicole Hamblin

Anthony William James Cooper

Simon Peace

Harry Finch

Andrew Sharpe

Michael D Dowle

Vipulkumar Kantibhai Patel

Kevin James Doyle

Lee Andrew Harrison

Niall Andrew Anderson

Martin Redpath Johnson

Kenneth David Down

Sebastien Andre Campos

Derek Anthony Demaine

Gemma Victoria White

Nicholas Paul Barton

Philip Alan Skone

Armelle Le Gall

Edward Paul Cannons

Diane Mary Coe

Ian B Campbell

Andrew McMurtrie Mason

Colin David Eldred

Gerard Martin Paul Giblin

Xiao Qing Lewell

James Michael Woolven

Pritom Shah

Gordon G Weingarten

David House

Heather Hobbs

Martin Edward Swarbrick

Gianpaolo Bravi

Iain McFarlane McLay

Rachel Elizabeth Hosking

Brian David Judkins

Simon Nicolle

Heather Anne Barnett

Haydn Terence Jones

Steven Philip Keeling

Ian Baxter Campbell

Gordon Gad Weingarten

Simon John Fawcett Macdonald

The invention relates to compounds of formula (I): wherein R, R, R, R, L and A are as defined in the description and claims, or pharmaceutically acceptable salts thereof having mTOR kinase inhibitor activity. The invention also relates to pharmaceutical compositions including a compound of formula (I) or a pharmaceutically acceptable salt thereof, and to the use of a compound of formula (I) or a pharmaceutically acceptable salt thereof in therapy, including in the treatment of a disease or condition for which an mTOR kinase inhibitor activity is indicated, and in particular the treatment of idiopathic pulmonary fibrosis.

Chemical compounds

The invention is directed to certain novel compounds. Specifically, the invention is directed to compounds of formula (I): and salts thereof. The compounds of the invention are inhibitors of kinase activity, in particular PI3-kinase activity.

The present invention provides compounds of formula (I): a process for their preparation, to pharmaceutical compositions comprising the compounds and the preparation of said compositions, to intermediates and to use of the compounds for the manufacture of a medicament for therapeutic treatment, particularly for the treatment of inflammation, allergy and/or autoimmune conditions.

Non-steroidal glucocorticoid inhibitors and their use in treating inflammation, allergy and auto-immune conditions

Indazoles as glucocorticoid receptor ligands

Compounds of formula (I) or salts or solvates thereof or physiologically functional derivatives thereof are potent binders at the EP4 receptor and are of use in the treatment or prevention of conditions such as a pain, inflammatory, immunological, bone, neurodegenerative or renal disorder.

Indole derivatives

Compounds of formula (I), methods for their preparation and their use in the manufacture of neuraminidase inhibitor conjugates. Wherein R represents as carboxylic acid protecting group; Pand Pcan be the same or different and are selected from amine protecting groups; Prepresents a protecting group for 1, 2 diols; and LG represents a leaving group 

Intermediates for preparing neuraminidase inhibitor conjugates

According to the invention are provided compounds of formula (I) (relative stereochemistry indicated) wherein R,, R,and R,are as defined in the specification. Compounds of formula (I) are useful inter alia in the treatment of inflammatory diseases of the respiratory tract.

Pyrrolopyrrolone derivatives as inhibitors of neutrophil elastase

According to the invention there are provided Hexahydro-Pyrrolo&lsqb;3,4-b&rsqb;pyrrol-2-one compounds of formula (1), (relative stereochemistry indicated), wherein R,, R,and R,are as defined in the specification. Compounds of formula (1) are useful inter alia in the treatment or chronic bronchitis.

Pyrrolopyrrolone derivatives

Growing community of inventors

Stevenage, United Kingdom

Graham George Adam Inglis